Is Semaglutide legal in Norway?

Semaglutide is among the peptides readers most often ask about in Norway. This page focuses on the regulatory reality there, not on how to obtain or use it, because that is where reliable, localized information is hardest to find.

In Norway, Semaglutide is an authorised, prescription-only medicine, regulated by DMP (Norwegian Medical Products Agency, formerly Statens legemiddelverk). It holds an EU-wide marketing authorisation granted through the European Medicines Agency (EMA), sold as Ozempic and Rybelsus for type-2 diabetes and Wegovy for weight management, valid across the EU and EEA (which is how it applies in Norway).

Semaglutide is supplied through pharmacies on prescription. Importing prescription medicines outside regulated channels is restricted, and customs may detain shipments. Holding Semaglutide on a valid prescription is lawful in Norway; obtaining or holding it without a prescription is not.

Selling or supplying Semaglutide without the required authorisation is an offence in Norway. DMP (Norwegian Medical Products Agency, formerly Statens legemiddelverk) sets out the applicable sanctions; we do not reproduce specific figures here because they change. Confirm the current penalties with the regulator. This page reflects our reading of the position as of the last-verified date; regulations change, so confirm with DMP (Norwegian Medical Products Agency, formerly Statens legemiddelverk) before making any decision.